(MENAFN- The Rio Times) Hypera Pharma reported a steep 74.2% drop in fourth-quarter profit from continuing operations, falling to R$79.5 million ($13.9 million) compared to the same period last year.

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ETCompany ParticipantsBreno Toledo Pires de Oliveira - Chief ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

MIRA Pharmaceuticals (MIRA) has signed a binding letter of intent to acquire SKNY Pharmaceuticals. The transaction includes a $5M capital ...

MIRA Pharmaceuticals (MIRA) announced that it has signed a binding letter of intent or LOI to acquire SKNY Pharmaceuticals… The transaction ...

Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science companies have at least experimented with one generative AI (GenAI ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.

The best logo maker is an essential design tool for anyone looking to differentiate their brand online. My round-up here offers apps ideal for designers and non-designers who need to help their ...